Literature DB >> 7356417

Dystonic foot response of Parkinsonism.

P A Nausieda, W J Weiner, H L Klawans.   

Abstract

One third of a patient population with idiopathic parkinsonism was found to suffer from debilitating, painful dystonic movements of the lower extremities. The prevalence of this involuntary movement disorder was found to be positively correlated with the duration of dopaminergic treatment, but it also occurred occasionally in untreated persons. We suggest that the "dystonic foot response of parkinsonism" is a distinct clinical entity that has no localizing value in frontal lobe disorders and is associated with extrapyramidal disease. This disorder, though exacerbated by dopaminergic therapy, also differs from well-accepted dopaminergic side-effects and does not predictably respond to manipulation of antiparkinsonian medications. Although the precise pathophysiology of this movement disorder is unknown, its response to baclofen therapy suggests that neurotransmitter systems other than cholinergic or dopaminergic ones may be implicated.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7356417     DOI: 10.1001/archneur.1980.00500520030003

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  14 in total

Review 1.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  The role of dopamine receptors in the neurobehavioral syndrome provoked by activation of L-type calcium channels in rodents.

Authors:  Suhail Kasim; Bonita L Blake; Xueliang Fan; Elena Chartoff; Kiyoshi Egami; George R Breese; Ellen J Hess; H A Jinnah
Journal:  Dev Neurosci       Date:  2006       Impact factor: 2.984

3.  Dysregulation of striatal dopamine release in a mouse model of dystonia.

Authors:  Li Bao; Jyoti C Patel; Ruth H Walker; Pullanipally Shashidharan; Margaret E Rice
Journal:  J Neurochem       Date:  2010-07-27       Impact factor: 5.372

Review 4.  It's not just the basal ganglia: Cerebellum as a target for dystonia therapeutics.

Authors:  Ambika Tewari; Rachel Fremont; Kamran Khodakhah
Journal:  Mov Disord       Date:  2017-08-26       Impact factor: 10.338

5.  Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.

Authors:  S A Factor; J R Sanchez-Ramos; W J Weiner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-04       Impact factor: 10.154

6.  Early diagnosis of Parkinson's disease.

Authors:  A M Bakheit
Journal:  Postgrad Med J       Date:  1995-03       Impact factor: 2.401

7.  The motor disorder of multiple system atrophy.

Authors:  N P Quinn; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-12       Impact factor: 10.154

8.  Kinesigenic foot dystonia as a presenting feature of Parkinson's disease.

Authors:  A J Lees; R J Hardie; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

Review 9.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

Review 10.  Attenuated variants of Lesch-Nyhan disease.

Authors:  H A Jinnah; Irene Ceballos-Picot; Rosa J Torres; Jasper E Visser; David J Schretlen; Alfonso Verdu; Laura E Laróvere; Chung-Jen Chen; Antonello Cossu; Chien-Hui Wu; Radhika Sampat; Shun-Jen Chang; Raquel Dodelson de Kremer; William Nyhan; James C Harris; Stephen G Reich; Juan G Puig
Journal:  Brain       Date:  2010-02-22       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.